Adaptimmune Therapeutics PLC (ADAPY) stock
ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.04+0.00 (+9.38%)
Close on Oct 19, 2026Market cap $55.46MP/E –Yield –
Adaptimmune Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Adaptimmune Therapeutics's free cash flow for the twelve months ending Jun 30, 2025 was -$191.67M. For fiscal 2024 it was -$74.09M. The highest annual figure on record is $35.47M in fiscal 2014.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$74.09M | – |
| FY2023 | Dec 31, 2023 | -$145.56M | – |
| FY2022 | Dec 31, 2022 | -$171.27M | -8047.3% |
| FY2021 | Dec 31, 2021 | $2.16M | – |
| FY2020 | Dec 31, 2020 | -$55.93M | – |
| FY2019 | Dec 31, 2019 | -$114.10M | – |
| FY2018 | Dec 31, 2018 | -$108.30M | – |
| FY2017 | Dec 31, 2017 | -$78.96M | – |
| FY2015 | Jun 30, 2015 | -$34.75M | -198.0% |
| FY2014 | Jun 30, 2014 | $35.47M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$34.86M | -174.2% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$67.80M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$34.42M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$54.59M | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $46.98M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$32.05M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$15.50M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$45.45M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$44.98M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$39.63M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$1.37M | -101.1% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$58.17M | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$50.21M | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$61.52M | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $129.91M | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$46.83M | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -$33.23M | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$47.69M | -386.2% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -$30.38M | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -$17.03M | – |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -$25.18M | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $16.67M | – |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -$12.70M | – |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | -$29.83M | -422.3% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | -$34.47M | – |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | -$37.11M | – |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | -$31.77M | – |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | $9.26M | -22.1% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | -$36.60M | – |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | -$49.18M | – |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | -$23.21M | – |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $11.89M | – |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | -$26.95M | – |
| Q1 FY2017CQ1 2017 | Mar 31, 2017 | -$40.69M | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | -$6.32M | – |
See a number that looks wrong?